Shots:

• ACEA to receive $250M in upfront cash as a total deal value- adding a differentiated portfolio and organizational capabilities in cell analysis
• Agilent will get hold of ACEA’s CFDA and CE-IVD labelled cytometer configuration- i.e. NovoCyte flow cytometer and xCELLigence Real-Time Cell analyzer used for monitoring growth- function- and cellular responses of cells
• The acquisition will expand Agilent’s R&D- manufacturing & operations- and commercial capabilities and coverage in China

Ref: Agilent Technologies | Image: Pr web